Form 4: Phibro Animal Health CEO Sells Shares via 10b5-1 Plan
Insider Transaction Report
Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC sold 5,752 Class A shares under a 10b5-1 plan.
Summary
- Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC (also a 10% Owner), reported sales of Class A Common Stock.
- The transactions occurred on December 11, 2025.
- A total of 5,752 shares were sold: 2,757 shares at a weighted average price of $40.6096 and 2,995 shares at a weighted average price of $41.2167.
- These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
- Following these transactions, Jack Bendheim directly holds 16,840 shares.
- BFI Co., LLC indirectly holds 42,195 shares and 39,200 shares, totaling 81,395 shares, over which Jack Bendheim exercises voting and dispositive power.
Sentiment
Score: 4
Explanation: Insider selling, even under a 10b5-1 plan, can be viewed with caution by investors, suggesting a potential lack of upside conviction from management. However, the pre-planned nature mitigates some of the immediate negative implications.
Positives
- The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new, undisclosed information.
Negatives
- Insider selling by a key executive (President and CEO) and a significant owner (10% owner) could be interpreted by the market as a lack of confidence or a signal that the stock price may be nearing a peak.
- The total value of shares sold is approximately $235,900, which is a notable amount.
Risks
- Negative investor sentiment or perception due to insider selling, potentially leading to downward pressure on the stock price.
- While executed under a 10b5-1 plan, the market may still view the divestment by a top executive as a bearish signal.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | Sales were conducted under a Rule 10b5-1 trading plan, a mechanism allowing insiders to sell shares without being accused of trading on material non-public information, demonstrating adherence to regulatory best practices. | 05/30/2025 | Enhances transparency and reduces the perception of opportunistic insider trading. |
Related Party Transactions
- The sales by BFI Co., LLC are considered related party transactions, as Jack Bendheim, a reporting person, director, and officer, exercises voting and dispositive power over BFI.
Stakeholder Impact
- Shareholders may interpret the insider selling as a signal regarding the company's future prospects or valuation, potentially influencing their investment decisions.
Key Dates
| Date | Description |
|---|---|
| 05/30/2025 | BFI Co., LLC adopted the Rule 10b5-1 trading plan. |
| 12/11/2025 | Date of the reported stock transactions (sales). |
| 12/15/2025 | Date the Form 4 was signed and filed. |
Keywords
PAHC, Phibro Animal Health, Jack Bendheim, BFI Co. LLC, insider trading, stock sale, 10b5-1 plan, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.